Camp4 Therapeutics (CAMP) EBIT Margin (2023 - 2026)

Camp4 Therapeutics has reported EBIT Margin for 4 years, with the latest figure at 1010.12% in Q1 2026.

• Quarterly EBIT Margin rose 51668.0% year-over-year to 1010.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1335.18% (up 219542.0% YoY) and the FY2025 annual result came in at 1502.43%, up 663990.0% from the prior year.
• EBIT Margin advanced to 1010.12% in Q1 2026 per CAMP's latest filing, from 3671.26% in the prior quarter.
• Over five years, EBIT Margin peaked at 870.27% in Q2 2025 and troughed at 3671.26% in Q4 2025.
• A 4-year average of 2067.6% and a median of 1717.11% in 2025 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin tumbled 151881 bps in 2025, then jumped 51668 bps in 2026.
• Over 4 years, EBIT Margin stood at 3525.14% in 2023, then soared by 39 bps to 2152.45% in 2024, then tumbled by 71 bps to 3671.26% in 2025, then jumped by 72 bps to 1010.12% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 1010.12%, 3671.26%, and 1717.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.